What's behind Abbott Laboratories's latest stock pullback?

Traders Union
All News
Stocks
Abbott laboratories slides 1.73% today

Highlights

Ieq Capital LLC acquired 191,459 shares of Abbott Laboratories in the second quarter, investing $17.37 million.
Abbott Laboratories declared a quarterly dividend of $0.63 per share, producing a 2.2% annualized yield.
Shares of Abbott Laboratories are trading near $110.51, with mixed momentum signals and an expected range of $107.81 to $113.21 over five days.

Institutional buying and earnings beat fail to counter broad selling

Ieq Capital LLC acquired a new position in Abbott Laboratories during the second quarter, purchasing approximately 191,459 shares valued at $17.37 million. The company also paid a quarterly dividend of $0.63 per share on August 17, 2023, giving an annualized yield of 2.2%. In the same period, OneAscent Financial Services LLC invested $544,000, acquiring 5,996 shares. Abbott Laboratories reported quarterly earnings per share of $1.31, exceeding consensus estimates, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees renewed short-term weakness in Abbott Laboratories despite strong institutional inflows and a positive earnings surprise. He notes that a break below the 20-day moving average with bearish MA-50 versus MA-200 alignment signals possible downside, even though longer-term technicals remain constructive. Kharitonov points out that oversold momentum and intraday selling pressure undermine confidence in a swift recovery. He cautions that short-term divergence across indicators could bring further volatility and pressure on support. "Further declines cannot be ruled out in the coming sessions as technical signals and sentiment still point to caution," he says.

Viktoras Karapetjanc, expert at Traders Union, views the fundamental backdrop for Abbott Laboratories as highly supportive following new institutional investment and a robust earnings beat. He considers the 2.2% annualized dividend yield and strong quarterly results as signals of resilience. Karapetjanc emphasizes that medium- and long-term bullish structure remains intact, with investor confidence evident in recent inflows. "I expect further growth opportunities as the market digests strong fundamentals, and a break above resistance could be the next catalyst," he says.

Jainam Mehta, market strategist, highlights the divergence between short-term technical weakness and medium-term support in Abbott Laboratories. He observes that mixed momentum and firm daily volatility set up a potential breakout above $111.18 resistance. Mehta suggests that tactical traders may find contrarian entry points if oversold signals persist. "I see room for sideways action with opportunities for nimble moves if momentum shifts," he says.

Mixed momentum signals as price tests major averages and support levels

Abbott Laboratories is trading below its 20-day moving average at $111.25, but remains above both the 50-day at $102.44 and the 200-day at $106.8, suggesting short-term downward pressure with a medium- and long-term bullish outlook. The nearest resistance is the ceiling at $111.18, while support is found at $109.87. The prevailing MA-50 versus MA-200 bearish alignment signals caution for longer-term positions. Momentum is mixed: the MACD and ADX both indicate strengthening upward momentum, while the RSI is in a neutral-to-bullish zone with a buy signal. The Stochastic RSI and Bull/Bear Power both indicate oversold conditions, though the BBP remains slightly positive, showing buyers still dominate intraday action. The Awesome Oscillator and Commodity Channel Index are neutral. Price action is near the session low, daily volatility is firm at 2.03%, and intraday tone reflects renewed pressure after the open. Divergence is apparent in the short-term signals.

Earlier, analysts noted that Abbott Laboratories maintained a bullish long-term structure despite near-term consolidation risks. The current technical setup reinforces this view, with mixed short-term signals but an ongoing upward probability, making the $111.18 resistance a pivotal level to monitor for potential breakout.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.